Earnings summaries and quarterly performance for Viking Therapeutics.
Executive leadership at Viking Therapeutics.
Board of directors at Viking Therapeutics.
Research analysts who have asked questions during Viking Therapeutics earnings calls.
Annabel Samimy
Stifel Financial Corp.
6 questions for VKTX
Also covers: ALT, APLS, CARA +14 more
Hardik Parikh
JPMorgan Chase & Co.
6 questions for VKTX
Also covers: PCRX, RPRX
Jay Olson
Oppenheimer & Co. Inc.
6 questions for VKTX
Also covers: ACAD, AMGN, BIIB +22 more
YJ
Yale Jen
Laidlaw & Company (UK) Ltd.
6 questions for VKTX
Also covers: AFMD, ALDX, ARCT +13 more
Justin Zelin
BTIG, LLC
5 questions for VKTX
Also covers: BCAB, CASI, GLMD +9 more
Mayank Mamtani
B. Riley Securities
5 questions for VKTX
Also covers: AGEN, ALT, ARWR +18 more
Ryan Deschner
Raymond James Financial
5 questions for VKTX
Also covers: APLS, ARDX, ARSP +7 more
JL
Joon Lee
Truist Securities
4 questions for VKTX
Also covers: ADVM, AXSM, CNM +14 more
AH
Andy Hsieh
William Blair & Company
3 questions for VKTX
Also covers: ALT, BYSI, CRDF +8 more
Biren Amin
Piper Sandler Companies
3 questions for VKTX
Also covers: ALLO, APLS, BBIO +5 more
MU
Michael Ulz
Morgan Stanley
3 questions for VKTX
Also covers: ALNY, ARWR, FATE +8 more
RS
Roger Song
Jefferies
3 questions for VKTX
Also covers: AADI, AKBA, ALT +13 more
Steve Seedhouse
Cantor Fitzgerald
3 questions for VKTX
Also covers: BCRX, BOLD, HROW +1 more
AR
Asim Rana
Truist Securities
2 questions for VKTX
Also covers: AXSM, CORT, CPRX +2 more
GF
George Farmer
Scotiabank
2 questions for VKTX
Also covers: ABSI, ADAP, INMB +7 more
JS
Jiale Song
Jefferies Financial Group Inc.
2 questions for VKTX
Also covers: ACRS, CRVS, CTMX +12 more
KP
Kushal Patel
Leerink
2 questions for VKTX
Rohit Bhasin
Morgan Stanley
2 questions for VKTX
Also covers: GUTS, MIRM
TS
Thomas Smith
Leerink Partners
2 questions for VKTX
Also covers: ACRS, ARGX, CLDX +5 more
TH
Tsan-Yu Hsieh
William Blair & Company
2 questions for VKTX
Also covers: AVIR, CRDF, EXEL +6 more
AR
Alexandra Ramsey
William Blair & Company, L.L.C.
1 question for VKTX
Also covers: NKTR
FG
Fiona Gia
Jefferies
1 question for VKTX
JM
Jeet Mukherjee
Leerink Partners
1 question for VKTX
Also covers: ARVN, BCAB, KURA +4 more
NC
Nat Charoensook
Leerink Partners
1 question for VKTX
Also covers: ARGX, IMUX
SS
Steven Seedhouse
Raymond James
1 question for VKTX
Also covers: APLS, BCRX, EDIT +2 more
Recent press releases and 8-K filings for VKTX.
Viking Therapeutics Completes Enrollment in VK2735 Maintenance Dosing Study
VKTX
New Projects/Investments
- Viking Therapeutics has completed patient enrollment in its exploratory maintenance dosing study for VK2735, a dual GLP-1 and GIP receptor agonist being developed for metabolic disorders such as obesity.
- The Phase 1 study, which enrolled approximately 180 adults, is designed to evaluate various subcutaneous and oral maintenance dosing regimens of VK2735 following initial weight loss.
- The primary objectives of the study are to assess the safety, tolerability, and pharmacokinetic profile of VK2735 under these regimens, with results expected later this year.
- This milestone comes as Viking is also conducting two Phase 3 trials for subcutaneous VK2735 (VANQUISH-1 and VANQUISH-2), with VANQUISH-1 having completed enrollment of approximately 4,650 adults.
3 hours ago
Viking Therapeutics Appoints Neil Aubuchon as Chief Commercial Officer
VKTX
Management Change
Hiring
- Viking Therapeutics announced the appointment of Neil Aubuchon as its new chief commercial officer on January 7, 2026.
- Mr. Aubuchon brings over two decades of biopharmaceutical industry experience, including leadership roles at AbCellera, Amgen, and Eli Lilly, with a focus on cardiometabolic and general medicine portfolios.
- His primary responsibility will be to lead the commercialization strategy for VK2735, Viking's GLP-1/GIP dual agonist currently in Phase 3 trials for obesity, and to engage with potential strategic partners.
1 day ago
VKTX Provides Updates on Obesity and Metabolic Disease Programs
VKTX
New Projects/Investments
- VKTX's oral VK2735 (GLP-1/GIP dual agonist for obesity) successfully completed its VENTURE Phase 2 study, achieving its primary endpoint with up to 14.7% mean weight loss after 13 weeks and demonstrating promising tolerability. An End of Phase 2 meeting with the FDA is scheduled for later this year.
- The injectable VK2735 formulation is progressing into Phase 3, with two VANQUISH studies initiated in 2Q25. Enrollment for VANQUISH 1 is complete, and VANQUISH 2 enrollment is expected to conclude in 1Q26.
- Other pipeline developments include successful Phase 2b data for VK2809 (MASH) reported in 2Q24 and successful Phase 1b data for VK0214 (X-ALD) reported in 4Q24. An Investigational New Drug (IND) application for an Amylin agonist for obesity is planned for 1Q26.
Nov 19, 2025, 12:00 PM
Viking Therapeutics Provides Update on VK2735 Obesity Programs and Financial Position
VKTX
New Projects/Investments
Guidance Update
- Viking Therapeutics is advancing VK2735, a GLP-1 GIP dual agonist, with its subcutaneous formulation in Phase III for obesity and an oral formulation having completed a Phase II study.
- Enrollment for the VANQUISH I Phase III study has been completed, and VANQUISH II is expected to complete enrollment in Q1 2026.
- The oral formulation of VK2735 demonstrated up to 12.2% body weight reduction after 13 weeks in its Phase II study, with an end-of-Phase II meeting with the FDA planned by year-end 2025.
- The company reported over $700 million in cash at the end of the third quarter, which is expected to fund operations through the VANQUISH Phase III data readouts.
Nov 19, 2025, 8:00 AM
Viking Therapeutics Updates on VK2735 Obesity Programs and Financials
VKTX
Product Launch
New Projects/Investments
- Viking Therapeutics' lead drug, VK2735, a GLP-1, GIP dual agonist for obesity, is progressing with both subcutaneous and oral formulations.
- The subcutaneous VK2735 is in Phase III (VANQUISH program), with VANQUISH-1 (obesity) having completed enrollment and VANQUISH-2 (obesity and type 2 diabetes) expected to complete enrollment in Q1 2026.
- The oral formulation of VK2735 recently completed a Phase II study, demonstrating up to 12.2% body weight reduction after 13 weeks and excellent tolerability; the company plans an end-of-Phase II meeting with the FDA by the end of 2025.
- The company reported over $700 million in cash at the end of Q3 2025, which is expected to fund operations through the VANQUISH Phase III data readouts.
Nov 19, 2025, 8:00 AM
Viking Therapeutics Provides Update on VK2735 Clinical Programs and Financial Position
VKTX
New Projects/Investments
Guidance Update
- Viking Therapeutics is focused on metabolic and endocrine disorders, with its lead program, VK2735, a GLP-1, GIP dual agonist for obesity, currently in Phase 3 trials for the subcutaneous formulation.
- Enrollment for the Vanquish One Phase 3 study has been completed, and enrollment for the Vanquish Two study is expected to be completed in Q1 2026.
- The oral formulation of VK2735 recently completed a Phase 2 study, demonstrating up to 12.2% body weight reduction after 13 weeks. The company plans an end-of-Phase 2 meeting with the FDA by the end of 2025 to determine next steps.
- Viking also has an amylin agonist approaching the clinic, with an Investigational New Drug (IND) filing expected in Q1 2026.
- The company reported over $700 million in cash at the end of Q3, which is expected to fund operations through the Vanquish Phase 3 data readouts.
Nov 19, 2025, 8:00 AM
Viking Therapeutics Completes Enrollment in Phase 3 VANQUISH-1 Trial
VKTX
Product Launch
New Projects/Investments
- Viking Therapeutics (VKTX) announced the completion of patient enrollment in its Phase 3 VANQUISH-1 clinical trial for subcutaneous VK2735, a dual GLP-1/GIP receptor agonist for obesity.
- The trial enrolled approximately 4,650 adults with obesity or who are overweight, completing ahead of schedule and above target size.
- The primary endpoint of the 78-week trial is the percent change in body weight from baseline.
- This follows positive results from the 2024 Phase 2 VENTURE study, where VK2735 demonstrated statistically significant mean body weight reductions of up to 14.7% after 13 weeks.
- The company expects to complete enrollment in its related Phase 3 VANQUISH-2 study in the first quarter of 2026.
Nov 19, 2025, 7:55 AM
Viking Therapeutics Highlights Positive VK2735 Cardiometabolic Data at ObesityWeek 2025
VKTX
- Viking Therapeutics announced new clinical data from its VK2735 obesity program at ObesityWeek® 2025, demonstrating improved cardiometabolic parameters.
- An exploratory analysis of the Phase 2 VENTURE trial showed that 78% of VK2735-treated prediabetic patients achieved normal glycemic status by Week 13, compared to 29% for placebo (p=0.0008).
- Additionally, 68% of VK2735-treated patients with metabolic syndrome (MetS) at baseline no longer met MetS criteria at Week 13, versus 38% for placebo (p=0.02).
- These findings complement previously reported significant mean body weight reductions of up to 14.7% and up to 88% of patients achieving ≥10% weight loss, highlighting VK2735's potential for comprehensive cardiometabolic health improvement.
- VK2735, a dual GLP-1/GIP receptor agonist, is currently being evaluated in a Phase 3 obesity program for its subcutaneous formulation.
Nov 6, 2025, 12:05 PM
Viking Therapeutics Reports Q3 2025 Financial Results and Provides Corporate Update
VKTX
Earnings
New Projects/Investments
- Viking Therapeutics reported a net loss of $90.8 million, or $0.81 per share, for the third quarter ended September 30, 2025, an increase from a net loss of $24.9 million, or $0.22 per share, in Q3 2024, primarily due to a rise in research and development expenses to $90.0 million from $22.8 million.
- The company maintained a strong quarter-end cash position of $715 million in cash, cash equivalents, and short-term investments as of September 30, 2025.
- Significant progress was made with the VK2735 obesity program, with Phase 3 VANQUISH trials for subcutaneous VK2735 proceeding on schedule and positive top-line results from the Phase 2 VENTURE-Oral Dosing study demonstrating up to 12.2% mean weight loss after 13 weeks.
- Viking plans to file an Investigational New Drug (IND) application for its amylin agonist program in the first quarter of 2026.
Oct 22, 2025, 8:10 PM
Viking Therapeutics Reports Q3 2025 Financial Results and Clinical Pipeline Updates
VKTX
Earnings
New Projects/Investments
- Viking Therapeutics reported a net loss of $90.8 million, or $0.81 per share, for the third quarter ended September 30, 2025.
- The company maintained a strong quarter-end cash position of $715 million as of September 30, 2025.
- Phase 3 VANQUISH trials for subcutaneous VK2735 in obesity are proceeding on schedule, with enrollment for VANQUISH-1 expected to complete by the end of 2025 and VANQUISH-2 in the first quarter of 2026.
- The Phase 2 VENTURE-Oral Dosing study of VK2735 successfully achieved its primary and secondary endpoints, demonstrating statistically significant reductions in body weight of up to 12.2% from baseline after 13 weeks.
- Viking plans to file an Investigational New Drug (IND) application for its dual amylin and calcitonin receptor agonist (DACRA) program in the first quarter of 2026.
Oct 22, 2025, 8:05 PM
Quarterly earnings call transcripts for Viking Therapeutics.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more